GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
ConditionHepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChinese Academy of Sciences
About this trial
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.
The main purposes of this study include:
① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.
② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients who have been diagnosed with hepatocellular carcinoma.
Planned to receive hepatectomy.
Liver function Child-Pugh A/B.
GPC-3 was validated highly expressed preoperatively.
Disqualifiers
Allergic to IRDye800.
Enrolled in other trials in the past 3 months.
Another malignant tumor was found.
Undesirable function of heart, lung, kidney, or any other organs.
Trial design
Design model
Single group
Treatments tested in this trial
Anti-GPC3-IRDye800CW
DrugDrug Injection: Anti-GPC3-IRDye800CW
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: Anti-GPC3-IRDye800CW Intraoperative FluorescenceExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
HCC lesions
Numbers of intraoperatively detected hepatocellular carcinoma lesions.
Time frame
During hepatocellular resection surgery.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov